Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,719.02
-6.5424-0.38%
Number of Gainers:- -
Number of Losers:2
Number of Flat:- -
PE:- -
High:1,742.20
Open:1,728.53
Low:1,717.08
Close:1,725.57
Volume:7.52M
Turnover:1.07B
Market Cap:443.02B
Float Cap:434.81B

Loading ...

Dow Jones Top Company Headlines at 9 PM ET: Amazon Cargo Plane Overshoots Runway in Miami, Killing Five People | Carmakers ...

Dow Jones
·
Sep 07

Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal

Dow Jones
·
Sep 05

Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex

Dow Jones
·
Sep 05

Novartis Pelacarsen Fails Phase III Cardiovascular Outcomes Trial

MT Newswires Live
·
Sep 05

Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

TIPRANKS
·
Sep 05

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Dow Jones
·
Sep 05

Novartis AG Falls Friday, Underperforms Market

Dow Jones
·
Sep 05

Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects

Dow Jones
·
Sep 04

Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...

Dow Jones
·
Sep 04

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 04

Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares

Reuters
·
Sep 03

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

TIPRANKS
·
Sep 03

Novartis AG Rises Wednesday, Outperforms Market

Dow Jones
·
Sep 03

Novartis, Alteogen Sign Drug-Technology Deal Worth Up to $3.2 Billion

MT Newswires Live
·
Sep 02

Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?

Simply Wall St.
·
Sep 02

Alteogen enters option, license agreement with Novartis

TIPRANKS
·
Sep 02

Novartis Trial Suspensions to Have Limited Financial Impact

Dow Jones
·
Sep 02

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 02

H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi

TIPRANKS
·
Sep 01

Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity

Dow Jones
·
Sep 01